HONG KONG, July 23, 2019 /PRNewswire/ -- Global Cord
Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced that
the Company filed its Annual Report on Form 20-F with the U.S.
Securities and Exchange Commission. The filed Form 20-F includes
audited financial statements for the fiscal year ended March 31, 2019. The Form 20-F can be accessed by
visiting the U.S. Securities and Exchange Commission's website at
http://www.sec.gov and also be found at the Investor Relations
section of GCBC's website at http://ir.globalcordbloodcorp.com.
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple
licenses. Under current People's
Republic of China government regulations, only one licensed
cord blood banking operator is permitted to operate in each
licensed region and no new licenses will be granted before 2020 in
addition to the seven licenses authorized as of today. Global
Cord Blood Corporation provides cord blood collection, laboratory
testing, hematopoietic stem cell processing, and stem cell storage
services. For more information, please visit our website at
http://www.globalcordbloodcorp.com.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com
ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-files-its-annual-report-on-form-20-f-300889264.html
SOURCE Global Cord Blood Corporation